Culture medium and culture method applied to breast cancer organoid of patient after chemotherapy

By using specific combinations of culture media and treatment steps, the problem of breast cancer organoid culture after chemotherapy was successfully solved, the success rate and cell morphology were improved, and its value in clinical research and application was expanded.

CN118931840APending Publication Date: 2024-11-12SECOND AFFILIATED HOSPITAL OF COLLEGE OF MEDICINEOF XIAN JIAOTONG UNIV
View PDF -1 Cites 0 Cited by

Patent Information

Application Number
CN202411017793.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively culture breast cancer organoids in patients after chemotherapy, resulting in low culture success rate and irregular cell morphology, limiting its value in clinical research and application.

Method used

A type of recombinant protein R-Spondin 3, head protein Noggin, cell growth factor, B27 additive, inhibitor, nicotinamide, acetylcysteine ​​N-Acetylcysteine, SOX2, CHIR99021 and recombinant were used The culture medium of protein Wnt3a, combined with specific cell processing steps, forms breast cancer organoids.

Benefits of technology

It improves the success rate of breast cancer organoid culture, forms spherical cell formation, short culture cycle, retains the heterogeneity of the patient's source tissue, reduces the culture cost, and provides accurate drug guidance for drug screening for patients after chemotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931840A_ABST
    Figure CN118931840A_ABST
Patent Text Reader

Abstract

The invention relates to a culture medium applied to breast cancer organoid of a patient after chemotherapy and a culture method of the culture medium, and belongs to the technical field of cell culture. The culture medium is prepared from the following components: a basic culture solution, Primocin, R-Spondin 3, Noggin, a cell growth factor, a B27 additive, an inhibitor, Nicotinamide, N-Acetylcysteine, SOX2, CHIR99021 and a recombinant protein Wnt3a. The invention further discloses a preparation method of the recombinant protein Wnt3a. In the embodiment, the SOX2 transcription factor participates in maintaining self-renewal and pluripotency of the embryonic stem cells; cHIR99021 is a GSK-3alpha / beta inhibitor and a Wnt / beta-catenin signal channel activator, and can be used for enhancing the self-renewal of human embryonic stem cells; the culture medium is high in culture success rate, the cultured organoid cell spheres are regular in sphere shape and short in culture period, and the heterogeneity of patient source tissues can be well reserved; the culture medium disclosed by the invention is relatively low in culture cost; the cultured organoid can be used for screening drugs for further treatment of patients after chemotherapy, and provides treatment guidance for precise medication of the patients.
Need to check novelty before this filing date? Find Prior Art